Joint Clinical Trials Office

You are here

EAY131: Molecular Analysis for Therapy Choice (MATCH)

Clinical Trial Details

This study is a type of basket trial designed with the flexibility to open and close subprotocols. The study drugs included in this trial include single agents and combinations that have at least a recommended phase 2 dose. Potential patients will have a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial will be offered participation on MATCH. 

Key Eligibility: 

Patients age 18 or older 
Not pregnant or breast feeding 
Histologically documented solid tumor or confirmed diagnosis of lymphoma or multiple myeloma requiring therapy 
Patient has progressed following at least one line of standard systemic therapy and there is not another approved/standard therapy available that has been shown to prolong overall survival. 
Patient's disease does not have a standard treatment known to prolong overall survival 
More detailed eligibility criteria when you contact the study team. 

Study contact by location

Upper East Side - Manhattan


June D. Greenberg, RN
(212) 746-2651

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:



Open to Enrollment